Company intelligence / Profile preview

UTime

Shenzhen, Guangdong, China

Ownership: Private
Development stage: Other

Overview

UTime is a Shenzhen-based company with a long history in low-cost mobile technology, since 2024 actively transforming health and wellness via innovative wearable medical devices. UTime is progressing toward acquisition of Bowen Therapeutics, which will add advanced vaccine R&D expertise (notably in the monkeypox vaccine field). No public clinical trial efficacy results have been disclosed as of August 2025.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineDevice
Industry: Biotech

Partnerships

Collaboration with Dr. Ehud Baron (noted medical expert)Partnership discussions with clinical trial organizations for vaccines

Beyond the preview

Go deeper on UTime.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UTime.

Explore the full profile